Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 199,760,704
  • Shares Outstanding, K 2,696,190
  • Annual Sales, $ 40,122 M
  • Annual Income, $ 2,394 M
  • 36-Month Beta 0.73
  • Price/Sales 5.01
  • Price/Cash Flow 13.06
  • Price/Book 6.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 1.04
  • Number of Estimates 5
  • High Estimate 1.07
  • Low Estimate 1.00
  • Prior Year 0.98
  • Growth Rate Est. (year over year) +6.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
66.10 +12.89%
on 10/25/18
75.99 -1.80%
on 11/09/18
+5.16 (+7.43%)
since 10/15/18
3-Month
66.10 +12.89%
on 10/25/18
75.99 -1.80%
on 11/09/18
+7.25 (+10.76%)
since 08/15/18
52-Week
52.83 +41.25%
on 04/03/18
75.99 -1.80%
on 11/09/18
+19.82 (+36.17%)
since 11/15/17

Most Recent Stories

More News
Merck's Keytruda Improves Survival in Esophageal Cancer Study

Merck's (MRK) Keytruda meets primary endpoint of overall survival in a phase III study evaluating it for the second-line treatment of advanced esophageal cancer.

MRK : 74.83 (+1.00%)
INCY : 64.76 (+0.95%)
AMGN : 192.46 (+1.10%)
GSK : 40.49 (-0.98%)
NewLink Genetics Announces Merck Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920 (rVSVDG-ZEBOV-GP) to U.S. Food and Drug Administration

In 2014 the Company entered into a license agreement with Merck to develop, manufacture and commercialize NewLink Genetics' Ebola vaccine candidate

MRK : 74.83 (+1.00%)
NLNK : 2.11 (+13.44%)
Global HIV Diagnostics and Therapeutics Markets Report 2018-2023 Featuring Abbott Laboratories, Bio-Rad Laboratories, Cipla, GSK, Merck & Co., Siemens Healthineers and Thermo Fisher Scientific

The "Diagnostics and Therapeutics for HIV: Global Markets" report has been added to ResearchAndMarkets.com's offering.

SIEGY : 57.8000 (+1.58%)
ABT : 70.33 (+1.33%)
MRK : 74.83 (+1.00%)
Merck (MRK) Stock Moves -0.7%: What You Should Know

Merck (MRK) closed the most recent trading day at $74.09, moving -0.7% from the previous trading session.

MRK : 74.83 (+1.00%)
AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study

AbbVie's (ABBV) Mavyret demonstrates high virologic cure rates in a study evaluating it for an expanded patient population.

JNJ : 144.39 (+0.10%)
MRK : 74.83 (+1.00%)
LLY : 111.99 (+1.99%)
ABBV : 90.18 (+2.12%)
Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA

PARP inhibitor makers get a boost following priority review for AstraZeneca???s (AZN) label expansion application for Lynparza as a first-line maintenance treatment for ovarian cancer.

AZN : 41.26 (-0.34%)
MRK : 74.83 (+1.00%)
CLVS : 15.55 (+3.12%)
TSRO : 26.74 (+2.89%)
Merck Starts Rolling BLA Submission for Ebola Vaccine V920

Merck (MRK) begins the rolling submission of a BLA for its investigational Ebola vaccine candidate V920 to the FDA.

MRK : 74.83 (+1.00%)
LLY : 111.99 (+1.99%)
INO : 5.00 (+1.83%)
BMY : 53.30 (+1.35%)
Merck's KEYTRUDA(R) (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS greater-than or equal to10)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Phase 3 KEYNOTE-181 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy in...

MRK : 74.83 (+1.00%)
Asthma and Allergy Foundation of America Elects Dr. Richard Murray as New Board Chair

The Asthma and Allergy Foundation of America (AAFA) announces the election of Dr. Richard K. Murray, MD, FACP as the new board chair. Dr. Murray has served as a leader on AAFA's board of directors since...

MRK : 74.83 (+1.00%)
AstraZeneca's Lynparza Gets Priority Review in 1st Line Use

AstraZeneca (AZN) and partner Merck's sNDA looking for label expansion of Lynparza in the first-line setting gets FDA's priority review.

AZN : 41.26 (-0.34%)
MRK : 74.83 (+1.00%)
CLVS : 15.55 (+3.12%)
TSRO : 26.74 (+2.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade MRK with:

Business Summary

Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies...

See More

Key Turning Points

2nd Resistance Point 75.52
1st Resistance Point 74.81
Last Price 74.81
1st Support Level 73.53
2nd Support Level 72.96

See More

52-Week High 75.99
Last Price 74.81
Fibonacci 61.8% 67.14
Fibonacci 50% 64.41
Fibonacci 38.2% 61.68
52-Week Low 52.83

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar